The efficacy of type 5 phosphodiesterase inhibitors (PDE5i) has been verified by countless studies, and indeed these drugs have been included kak?m the first-line treatment for the management of erectile dysfunction (ED).1 It is therefore unsurprising that the general population saf heard about these drugs, including patients with a very limited aw